SUMMARY
Resident memory T cells (TRM) present at the respiratory tract may be essential to enhance early SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term antigen (Ag)-specific TRM are detectable beyond 11 months in the lung of convalescent COVID-19 patients after mild and severe infection1, it is unknown if mRNA vaccination encoding for the SARS-CoV-2 S-protein can induce this frontline protection. We found that the frequency of CD4+ T cells secreting interferon (IFN)γ in response to S-peptides was similar in the lung of mRNA-vaccinated patients compared to convalescent-infected patients. However, in vaccinated patients, lung responses presented less frequently a TRM phenotype compared to convalescent infected individuals and polyfunctional TRM were virtually absent. Thus, a robust and wide TRM response established in convalescent-infected individuals may be advantageous in limiting disease if the virus is not block by initial mechanisms of protection, such as neutralization. Still, mRNA vaccines can induce modest responses within the lung parenchyma potentially contributing to the overall disease control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from Fundacio La Marato TV3 (201814-10 FMTV3 and 202112-30 FMTV3), from the Health department of the Government of Catalonia (DGRIS 1_5), and the Spanish AIDS network Red Tematica Cooperativa de Investigacion en SIDA (RD16/0025/0007). M.J.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in accordance with the Declaration of Helsinki and approved by the corresponding Institutional Review Board (PR(AG)212/2020) of the Vall Hebron University Hospital (HUVH), Barcelona, Spain. Written informed consent was provided by all patients recruited to this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
